Peripheral T-Cell Lymphoma (PTCL) is a diverse group of aggressive lymphomas, which develop from mature T-cells and natural killer (NK) cells. PTCL is classified as a subtype of non-Hodgkin’s lymphoma (NHL). NHL affects two particular types of white blood cells: B-cells and T-cells. PTCL specifically affects T-cells and results when T-cells develop and increase abnormally. The most common subtype is called PTCL-not-otherwise specified (PTCL-NOS) and is most frequently diagnosed in individuals living in North America and Europe.
Peripheral T-Cell Lymphoma Epidemiological Segmentation
The Epidemiological Segmentation of Peripheral T-Cell Lymphoma in 7MM from 2017 to 2030 is segmented as:-
- Total Incident Cases of Peripheral T-cell Lymphoma (PTCL)
- Stage-Specific Incident Cases of Peripheral T-cell Lymphoma (PTCL)
- Subtype-Specific Incident Cases of Peripheral T-cell Lymphoma (PTCL)
Peripheral T-Cell Lymphoma Epidemiology
- PTCL accounts for 10–15% of all non-Hodgkin lymphomas worldwide.
- The total incident population of Peripheral T-Cell Lymphoma (PTCL) in 7MM in 2017 was 16,298
- PTCL accounts for 7–15% of NHLs in the United States and EU-5 countries
- EU5 countries occupied around 28.48% of the patient pool amongst 7MM in 2017
Peripheral T-Cell Lymphoma Market
The market size of PTCL in 7MM in 2017 was USD 815.38 Million
Peripheral T-Cell Lymphoma Market Drivers
- Use of Combination Therapies
- Upcoming novel therapies in pipeline for the treatment of PTCL
- An upsurge in Research and Development
Peripheral T-Cell Lymphoma Market Barriers
- Low rates of incidence
- Less expertise in diagnosis and rarity of PTCL subtypes
- Lack of awareness
Peripheral T-Cell Lymphoma Emerging Drugs
The Emerging drugs of the Peripheral T-Cell Lymphoma market are
- Denileukin diftitox
- SP-02 (Darinaparsin, ZIO-101)
- Fenretinide (4-HPR)
- Tipifarnib
- HBI-8000
- COPIKTRA (Duvelisib)
- Genolimzumab (GB226)
- Azacitidine (CC-486)
- Tislelizumab
- Lacutamab/IPH4102
- AFM13
- Opdivo (nivolumab) + Cabiralizumab
- Bavencio (avelumab)
- Keytruda (pembrolizumab): STI-3031/IMC-001
- ALRN 6924
- Masitinib
- Ruxolitinib
- Aplidin (plitidepsin)
ASTX660: And many others.
Peripheral T-Cell Lymphoma Key Players
The key players in the Peripheral T-Cell Lymphoma market are
- Eisai
- Solasia Pharma
- CerRx
- Kura Oncology
- HUYA Bioscience International/Quintiles, Inc
- Verastem
- Genor Biopharma
- Celgene Corporation
- BeiGene
- Innate Pharma
- Affimed GmbH
- Bristol-Myers Squibb
- Pfizer
- Merck Sharp & Dohme Corp.
- Sorrento Therapeutics
- Aileron Therapeutics
- AB Science
- Incyte Corporation/Novartis
- PharmaMar
- Otsuka Pharmaceutical
- Astex Pharmaceuticals
And many others.